KRAS Tests Market is gaining importance as molecular diagnostics become increasingly integrated into cancer treatment pathways. KRAS mutation testing provides genetic information that can help characterize tumors and support the selection of appropriate therapeutic strategies.

Colorectal cancer and lung cancer remain important areas for KRAS testing, while research is expanding into additional tumor types and emerging KRAS-targeted treatments. Testing can also play a role in clinical trials by helping researchers identify patients with specific molecular characteristics.

Laboratories are adopting technologies such as PCR and next-generation sequencing to detect KRAS alterations. These platforms can provide targeted mutation analysis or broader genomic profiling depending on clinical and research requirements.

Increasing investment in precision oncology, companion diagnostics, and targeted drug development is creating opportunities for the KRAS testing segment. Advances in molecular workflows and faster diagnostic technologies may further strengthen the role of KRAS analysis in cancer care.